Adjuvant Chemotherapy in Colon Cancer.
- Author:
Sang Hee CHO
1
Author Information
1. Division of Hematooncology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. shcho@chonnam.ac.kr
- Publication Type:Review
- Keywords:
Colon cancer;
Adjuvant chemotherapy
- MeSH:
Camptothecin;
Chemotherapy, Adjuvant;
Colon;
Colonic Neoplasms;
Colorectal Neoplasms;
Korea;
Organoplatinum Compounds;
Public Health;
Recurrence;
Standard of Care
- From:Korean Journal of Medicine
2012;83(3):297-304
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Colorectal cancer represents a major public health problem in worldwide including Korea. According to the National Cancer Registry, colon cancer is the third most common cancer and the forth leading cause of cancer death. The surgery is a main treatment option for cure. Despite curative surgery in those presenting early, the risk of relapse is significantly high. To improve the survival, huge advances have been made in the treatment of colon cancer over the last decade. Especially, the median overall survival time for stage IV colon cancer has been reached from 6-9 months to over 20 months. Based on these results, drugs such as irinotecan, oxaliplatin and oral fluoropyrimidine have been used to evaluate the efficacy in adjuvant setting. Oxaliplatin based chemotherapy is now emerging as the standard of care in adjuvant treatment of stage III colon cancer. Targeted agents, which have shown promise in the metastatic setting, are currently being examined in the adjuvant setting, although results have been disappointing until now. Even though adjuvant treatment is recommended for 'high risk' stage II, the endeavor to answer for question-who should be treated by what-is needed.
